Lenvima (lenvatinib) — United Healthcare
Hepatocellular carcinoma
Initial criteria
- Diagnosis of hepatocellular carcinoma
- Disease is unresectable or metastatic
Reauthorization criteria
- Patient does not show evidence of progressive disease while on Lenvima therapy
Approval duration
12 months